Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech binary events -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (80)	8/11/2003 7:52:50 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 295

Bottom line, IF I am shark I will be concerned? <g>

To: scaram(o)uche who wrote (80)	8/12/2003 9:28:30 AM
From: Icebrg	Read Replies (2) \| Respond to of 295

>>As you probably know, shark cartilage projects have been around for a long time. >> They may have been, but I haven't. This is actually my first contact with the stuff. There is an interesting article in John Hopkin's magazine on how it all started. The person who did the first cartilage experiments was no-one less than Judah Folkman. After that quacks like Lane has taken over most of the running. Predators Promise jhu.edu >>did AEOL get it from Bioimmune>> I don't think so. AEterna is, through the Atrium sub, distributing a number of more or less doubtful products. One of them is "CarTCell, a cartilage liquid extract with Scientifically Proven Oral bioavailability". atrium-bio.com I believe the birth of Neovastat represented a further "refinement" of the CarTCell's production process. >>Patent position possible?>> Aeterna have been issued a couple of patents - mainly production oriented. Æterna's patent portfolio now includes five patents issued in the United States. Patent 5,618,925 contains 28 claims that cover various processes of making extracts from cartilage having an antiangiogenic activity and an effect on tumor regression. This patent also covers the process for the preparation of Æ-941/Neovastat. Patent 5,985,839 contains 57 claims that principally cover various soluble cartilage fractions, comprising the Æ-941/Neovastat, made by various processes having an antiangiogenic activity and an effect on tumor regression. It also covers methods of using these extracts in treating skin diseases that are related to angiogenesis, and tumor proliferation. Patent 6,025,334 contains 28 claims that cover two new activities obtained from cartilage extracts, the anticollagenolytic and the anti-inflammatory activities. It also covers an improved process of preparation of cartilage extracts for topical formulations. It further contains claims that cover process of preparation of cartilage extract made with other species. Patent 6,028,118 contains 12 claims that cover methods for treating various skin disorders by topical application. The fifth one, USP 6,168,807 contains 17 claims that cover a new process for the preparation of extracts with organic solvents. These patents have also been filed in several countries. Almost everything in connection with Neovastat points in the direction of this being if not a scam so at least a very optimistic approach to the treatment of cancers. I used to believe that the involvement of NCI was something of a proof of seriousness, but judging from the John Hopkin article, NCI would just be as happy to disprove the notion. They even started a trial using Lane's cartilage powder. What remains is the fact that the lead investigators appears to be experienced people who take the efforts seriously. The key question in my mind is the condition of the patients drafted into participation of the study. If Bernhard Escudier - who has worked for many years with RCC and prognostic factors in connection with this disease - is not completely mistaken with regard to the expected medium survival time for the patient population in this trial, then the trial has indeed carried on for a longer period of time than what could be expected. Which should translate into a positive treatment effect from Neovastat. It is at least entertaining with a trial that is a little bit out of the ordinary. If they do indeed succeed, it would be very good news for cancer patients and open up new avenues for cancer treatment, but it would be very bad news for sharks. Erik